Drug intelligence / Profile preview

compound 3d

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

Compound 3d is a synthetic small molecule prodrug that is phosphorylated in vivo to form an active metabolite acting as a potent sphingosine-1-phosphate receptor modulator. It was developed through optimization of prior S1P1 modulators and is projected to have a human half-life of approximately five days. The primary indication under investigation for compound 3d is multiple sclerosis, leveraging its immunomodulatory effects via modulation of the sphingosine-1-phosphate receptor pathway. The development was led by Bristol-Myers Squibb[1].

Targets

S1PR5 (Sphingosine-1-phosphate receptor 5)S1PR3 (Sphingosine 1-phosphate receptor 3)

Beyond the preview

Go deeper on compound 3d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 3d.

Explore the full profile